1. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma. Issue 1 (December 2017) Authors: Jebali, M.; Elaidi, R.; Brizard, M.; Fouque, J.; Takouchop, C.; Sabatier, B.; Oudard, S.; Medioni, J. Journal: BMC cancer Issue: Volume 17:Issue 1(2017) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗